Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
WILMINGTON, Del., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the fiscal year ended December 31, 2023, and outlined key objectives for 2024.
- “Our partnership with AbCellera represents a strategic step to expand our pipeline, based on our core competencies in medicinal chemistry, cancer biology and clinical development.
- A second cohort of patients with AML is expected to initiate in the first half of 2024.
- Under the terms of the agreement, Prelude and AbCellera will jointly discover, develop, and commercialize products emerging from the collaboration.
- The decrease in general and administrative expenses was primarily due to our continued management of general and administrative expenses.